MED-EL Launches World’s First Commercially Available Totally Invisible Cochlear Implant
29.9.2026 14:00:00 CEST | news aktuell GmbH | Press Release
- World's first and only commercially available cochlear implant with all components implanted beneath the skin
- Continuous hearing day and night
- Hearing performance designed to be the same as established cochlear implant solutions
September 29, 2026 – (Innsbruck, Austria): MED-EL, a global leader in hearing implant technology, today announced the launch of TICI UNICO, the world's first and only commercially available totally invisible cochlear implant. Designed for people with severe-to-profound hearing loss, TICI UNICO enables continuous hearing 24 hours a day while remaining completely beneath the skin. It has received CE Mark approval and is being introduced in European markets.

Cochlear implants have helped hundreds of thousands of people worldwide to hear. TICI UNICO expands hearing implant options by combining continuous hearing with complete invisibility and freedom from external audio processors. Users can hear while sleeping, exercising, showering, swimming and charging the device.
"TICI UNICO is a new chapter in the history of hearing," says Dr. Ingeborg Hochmair, co-founder and CEO of MED-EL. "For the first time, invisible hearing with a cochlear implant is possible. This is a milestone for people with hearing loss and the result of decades of research and innovation at MED-EL.”
Key benefits of TICI UNICO:
- Completely invisible
- 24/7 access to sound
- No external equipment to wear, remove, or maintain
- No concerns about losing or damaging external devices
- Hearing performance comparable to established cochlear implant solutions
Long-Held Vision becomes Reality
Capturing sound through the skin has long been one of the greatest challenges in developing a totally invisible cochlear implant. MED-EL successfully developed an innovative microphone technology designed to deliver high-quality sound while remaining completely beneath the skin.
Prof. Philippe Lefèbvre, Head of the ENT Department at CHU Liège, and Prof. Joachim Müller, Associate Professor for Otology and Cochlear Implants at LMU University Hospital Munich, highlight the significance of TICI UNICO: “Twenty-four-hour, invisible hearing opens the door to a completely new generation of hearing implants.”
For recipients, the impact extends to the freedom of hearing. Thomas, one of the first TICI UNICO recipients, says: ”I wake up hearing, fall asleep hearing, and can enjoy everyday moments without having to think about my hearing device.”
TICI UNICO is intended for people with severe-to-profound sensorineural hearing loss who may benefit from a cochlear implant. More information: http://go.medel.com/tici.
Contacts
Silke ArtnerPR & Corporate Communications
Tel:+43 577880press@medel.comwww.medel.com/press-roomImages
About MED-EL
The Austrian-based, privately owned company MED-EL was co-founded by cochlear implant pioneers Ingeborg and Erwin Hochmair. To date, MED-EL has more than 3,300 employees from around 90 nations and 30 locations worldwide.
Users in 142 countries hear with a MED-EL device. www.medel.com
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Munich Arena breaks ground, marking a new era for live music in Europe29.10.2026 16:12:11 CET | Press Release
20,000 capacity "Music first" venue: The Munich Arena will be Germany's first concert arena specifically designed for music and live entertainment. The combination of striking architecture, exceptional acoustics, excellent sightlines, premium hospitality and world-class production facilities for artists and promoters will make Munich Arena one of Europe’s leading live music venues. Economic impact of €355 million per year: Munich Arena will boost the economy and culture for Munich and Bavaria, a Deloitte study estimates the economic impact to be around €355 million per year when the venue is open. Countdown to the opening in 2029 has begun: Freising’s lord mayor Monika Schwind joined Marek Lieberberg, President Live Nation GSA, Tom Lynch, President Live Nation Venues, Lorenz Schmid, Managing Partner Munich Arena, and Bavarian Prime Minister Dr. Markus Söder to officially break ground on Munich Arena. A supporter of Munich’s Olympic concept and the Free State of Bavaria:. Munich Arena i
Stay in your home region, seize new opportunities: EUstay presents ten EU-funded projects29.10.2026 14:45:31 CET | Press Release
Regional opportunities across Europe are at the centre of multimedia content packages on ten EU-funded Interreg projects. The content is provided for use to local media and stakeholders.
Flamingo-1: Germany’s First Space-Based SDA Telescope Delivers Commercial Space Surveillance and Tracking29.10.2026 10:22:14 CET | Press Release
Munich, October 29th, 2026 – Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has entered routine operations with its Flamingo-1 satellite. The satellite operates at a high duty cycle, continuously monitoring space objects, scouting for threats from low Earth orbit (LEO) to geostationary Earth orbit (GEO). The space-based image data generated by Flamingo-1 is further processed by Vyoma into products, services and intelligence in high demand among the SDA community and Vyoma’s customers to better understand the space domain from both a safety and a security perspective. The information is delivered to the company’s customers through the Vyoma Services Platform. Flamingo-1 operates both in surveillance and in tracking mode. In surveillance mode, the satellite continuously screens a large volume of space, setting it apart from ground-based optical systems that are idle during the day or when obstructed by bad weather. This high volume of data is ideal fo
Grünenthal presents Phase III results for Qutenza® in post-surgical neuropathic pain at IASP 2026 World Congress on Pain28.10.2026 09:30:00 CET | Press Release
Late-breaking data from the Phase III RISE trial further strengthen the well-established efficacy and safety profile of Qutenza®. Post-surgical neuropathic pain is a debilitating complication of surgery affecting millions of patients every year.¹ Aachen, Germany, 28 October 2026 – Grünenthal, a global leader in pain management and research, today announced new data from the Phase III RISE trial (NCT04967664), evaluating Qutenza® versus control in people with post-surgical neuropathic pain. These data were shared today as late-breaking poster presentations at the 2026 International Association for the Study of Pain (IASP) World Congress on Pain in Bangkok, Thailand. The trial (n=409) showed that Qutenza® achieved a statistically significantly greater reduction in average pain intensity (API) than the control treatment over weeks 2-12, meeting one of its pre-specified primary endpoints. When evaluating API at week 12 specifically, at the point when patients would typically return for ret
Webasto Air Top Pro 25: a new, exceptionally quiet parking heater for campers22.10.2026 13:28:00 CEST | Press Release
Why should the camping season end just because summer is over? The colder months offer unique experiences—from skiing and snowshoeing to simply enjoying the winter landscape. To ensure your motorhome or campervan remains a comfortable retreat even in low temperatures, the right heating solution is crucial.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom

